Drug Info Lab
Across
- 2. Oral agent for relapsed refractory FLT-3 AML
- 4. Prevents hemorrhagic cystitis for ifosfamide
- 6. Available as implantable wafers
- 7. Indication for sipuleucel-T
- 9. Anti-CD38 for multiple myeloma
- 10. Should never be administered intrathecally
- 11. Treats breast cancer; increases risk of endometrial cancer
- 12. PARP inhibitor with the most indications
- 13. Treatment for ALL that engages T-cells
- 16. Used in treatment of testicular cancer; can cause pulmonary toxicity
- 17. Virus attenuated in talimogene laherparepvec
- 19. Oral version of dacarbazine
- 20. Oral agent for advanced/metastatic breast cancer that requires monitoring of CBC for first two months
Down
- 1. Used to treat acute phase of irinotecan-induced diarrhea
- 3. ALK inhibitor that can treat the mutation T315I
- 5. Monoclonal antibody conjugate used for core binding factor AML
- 8. Side effect of cetuximab that can indicate therapy is benefitting
- 14. MEK inhibitor that is combined with dabrafenib
- 15. Highly emetogenic; can cause tinnitus
- 18. Treatment for CLL, requires monitoring for tumor lysis syndrome